Forest Labs upgraded to Outperform from Neutral at Cowen

theflyonthewall.com

Cowen now believes Forest Labs will be able to resolve its Bystolic litigation with all generic challengers and views its respiratory franchise as undervalued.

Rates

View Comments (0)